2023 World Conference on Lung Cancer (Posters)-EP10.01. Evaluating Osimertinib Induced Pneumonitis in EGFR Advanced Lung Cancer in a Real World Clinical Practice.

EP10.01. Evaluating Osimertinib Induced Pneumonitis in EGFR Advanced Lung Cancer in a Real World Clinical Practice. - PDF(Abstract)

Back to course

Pdf Summary

This study examined the occurrence of Osimertinib induced pneumonitis (OIP) in patients with EGFR advanced lung cancer. OIP is a serious adverse effect of Osimertinib therapy, but little is known about its clinical characteristics and radiographic findings. The researchers conducted a retrospective cohort study of 100 lung cancer patients treated with Osimertinib. They collected data on patient demographics, tumor genetics, radiographic findings, and treatment variables. They categorized lung findings while on Osimertinib based on morphology and assessed clinical history and final diagnosis. <br /><br />The results showed that among the 100 patients treated with Osimertinib, 28% had abnormal lung markings while on the medication. These markings were predominantly ground glass opacities, consolidations, nodular, and septal thickening. Patients with suspicion of pneumonitis had multi-lobar inflammatory changes. However, there was no suspicion of OIP among the patients who did not develop new respiratory symptoms. <br /><br />Of the 16 patients who developed respiratory symptoms, 12 had new infiltrates on pre-progression CT imaging and 6 had clinical suspicion for OIP. However, no patient in the study underwent a lung biopsy to confirm pneumonitis due to rapid development of hypoxemia. The median duration of Osimertinib therapy in this group was 7.54 months. <br /><br />The median overall survival (OS) of patients treated with Osimertinib in the study was 47.41 months, compared to 3.63 months among patients with clinical suspicion of OIP. <br /><br />In conclusion, this study found that OIP is a fulminant and rapidly fatal complication in patients with EGFR advanced lung cancer treated with Osimertinib. The diagnosis of OIP relied on the presence of new diffuse infiltrates early in the use of Osimertinib, along with associated hypoxia. The study also highlighted that inflammatory changes observed on CT imaging are not predictive of pneumonitis and that Osimertinib is safe to use in patients when such markings are incidentally identified in the absence of worsening respiratory symptoms.

Asset Subtitle

Shawn Ali

Meta Tag

Speaker Shawn Ali

Topic Metastatic NSCLC: Cytotoxic Therapy

Keywords

Osimertinib induced pneumonitis

EGFR advanced lung cancer

adverse effect

radiographic findings

retrospective cohort study

lung markings

respiratory symptoms

pre-progression CT imaging

lung biopsy

overall survival